Cellectar Biosciences Inc - Company Profile
Powered by 
All the data and insights you need on Cellectar Biosciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Cellectar Biosciences Inc Strategy Report
- Understand Cellectar Biosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Cellectar Biosciences Inc (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform develops PDCs for the treatment and diagnosis of cancer. Its lead product includes CLR 131, is a small-molecule PDC, in Phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas, malignant brain tumors, head and neck cancer. Cellectar’s other products in the pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors and oncology indications. The company has collaborations with Orano Med, Onconova Therapeutics, Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.
Headquarters
United States of America
Address
100 Campus Drive, Florham Park, New Jersey, 07932
Website
www.cellectar.com
Telephone
1 608 4418120
No of Employees
15
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CLRB (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-32.8%
(2022 vs 2021)
Market Cap*
$113.2M
* As of and is in US$
Cellectar Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| CLR 131- Multiple Myeloma, B-Cell Lymphomas, Pediatric and Head and Neck Cancer |
| CLR 1800- Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Florida Cancer Specialists & Research Institute to help with Waldenstrom's Macroglobulinemia care in local communities. |
| 2021 | Contracts/Agreements | In August, the company and Evergreen Theragnostics entered into a commercial manufacturing and supply agreement for the supply of iopofosine I-131 and supply of clinical study material for Cellectar’s pivotal study in Waldenstrom’s macroglobulinemia. |
| 2021 | Contracts/Agreements | In July, the company entered into an agreement with IntoCell Inc. to globally develop and commercialize any OHPAS containing PDC. |
Competitor Comparison
| Key Parameters | Cellectar Biosciences Inc | Seagen Inc | Exelixis Inc | MEI Pharma Inc | Avelas Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Florham Park | Bothell | Alameda | San Diego | La Jolla |
| State/Province | New Jersey | Washington | California | California | California |
| No. of Employees | 15 | 3,256 | 1,310 | 46 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Douglas J. Swirsky | Director; Chairman | Executive Board | 2017 | 53 |
| James V. Caruso | Chief Executive Officer; Director; President | Executive Board | 2015 | 64 |
| Chad J. Kolean | Chief Financial Officer; Vice President; Secretary | Senior Management | 2022 | 58 |
| Jarrod Longcor | Chief Operating Officer | Senior Management | 2022 | 50 |
| Shane Lea | Chief Commercial Officer | Senior Management | 2022 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward